Triple-negative breast cancer: Risk factors to potential targets

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8010-8018

  Schneider, Bryan P ^a,e   Winer, Eric P ^b   Foulkes, William D ^c   Garber, Judy ^b   Perou, Charles M ^d   Richardson, Andrea ^b   Sledge, George W ^a   Carey, Lisa A ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e Indiana Cancer Pavilion   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; BRCA1 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; PACLITAXEL; SUNITINIB; TAXANE DERIVATIVE; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CHEMISTRY; FEMALE; GENETICS; RISK FACTOR; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 58149359842     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1208     Document Type: Review

References (64)

1. Olopade OI, Nanda R, GrushkoT. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 2008;14:7988-99.
2. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
3. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA2001;98:10869-74.
4. Nielsen TO, Hsu FD, Jensen K, et al. Immunohisto- chemical and clinical characterization of the basal-like subty pe of in vasivebreast carcinoma.ClinCancerRes 2004;10:5367-74.
5. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
6. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008;52:108-18.
7. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-32.
8. Moyano JV, Evans JR, Chen F, et al. α B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006;116: 261 -70.
9. Sitterding SM, Wiseman WR, Schiller CL, et al. αB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol 2008;12:33-40.
10. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008;14:5158-65.
11. Gusterson BA, Warburton MJ, Mitchell D, Ellison M, NevilleAM, Rudland PS. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. CancerRes1982;42: 4763-70.
12. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11 -24.
13. Sorlie T, Tibshirani R, Parker J, et al. Repeatedobser- vation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A2003; 100:8418-23.
14. Bergamaschi A, Kim YH, Wang P, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-xpression subtypes of breast cancer.Genes Chromo-somes Cancer 2006;45:1033-40.
15. Chin K, DeVries S, Fridly and J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41.
16. Han W, Jung EM, Cho J, et al. DNA copy number alterations and expression of relevant genes in triple- negative breast cancer. Genes Chromosomes Cancer 2008;47:490-9.
17. Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepi- thelial cell differentiation. Br J Cancer 2001;85:422-7.
18. Gauthier ML, Berman HK, Miller C, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. CancerCell 2007;12:479-91.
19. Herschkowitz J, He X, Fan C, Perou C. The functional lossoftheretinoblastomatumorsuppressorisacommon event in basal-like and luminal B breast cancers. Breast Cancer Res 2008;105:R75. [Epub ahead of print].
20. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phe- notype in breast cancer. J Natl Cancer Inst 2003;95: 1482-5.
21. +) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-5.
22. Turner N, Tutt A, Ashworth A. Hallmarks of ''BRCA-ness'' in sporadic cancers. Nat Rev Cancer 2004;4: 814-9.
23. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006;25: 5846-53.
24. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2.
25. Katagiri T, Emi M, Ito I, et al. Mutations intheBRCA1 gene in Japanese breast cancer patients. Hum Mutat 1996;7:334-9.
26. Catteau A, Harris WH, Xu CF, Solomon E. Methyla- tion of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999;18:1957-65.
27. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92:564-9.
28. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 2005;91:179-86.
29. Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006;9:121 -32.
30. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-8.
31. Wright MH, Robles AI, Herschkowitz JI, et al. Molecular analysis reveals heterogeneity of mousemammary tumors conditionally mutant for Brca1. Mol Cancer 2008;7:29.
32. Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029-34.
33. Kriege M, Seynaeve C, Meijers-Heijboer H, et al. Distant disease-free interval, site of first relapse and post-relapsesurvivalin BRCA1- andBRCA2-associat- ed compared to sporadic breast cancer patients. Breast CancerResTreat 2008;111:303-11.
34. Luck AA, Evans AJ, Green AR, Rakha EA, Paish C, EllisIO. Theinfluenceofbasal phenotypeon themeta- static pattern of breast cancer. Clin Oncol R Coll Radiol 2008;20:40-5.
35. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447: 1087-93.
36. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 16q12 confersus-ceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007;39:865-9.
37. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor (ER) status. Clin Cancer Res 2008;14:8000-9.
38. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109:1721 -8.
39. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2008 Mar 7. Epub ahead ofprint.
40. Millikan RC, Newman B,Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer ResTreat 2008;109:123-39.
41. Morris GJ, Naidu S, Topham AK, et al. Differencesin breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Resultsdatabase. Cancer2007;110:876-84.
42. Yang XR, Pfeiffer RM, Garcia-Closas M, et al. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res 2007;67:10608-17.
43. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomar kers Prev 2007;16:439-43.
44. Weigelt B, Horlings H, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216: 141 -50.
45. Collett K, Stefansson IM, EideJ, et al. Abasal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. CancerEpidemiol Biomarkers Prev2005;14:1108-12.
46. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26: 2568-81.
47. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin CancerRes2007;13:4429-34.
48. Liedtke C, Mazouni C, HessKR, et al. Responseto neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26:1275-81.
49. Hayes DF, Thor AD, Dressler LG, et al. HER2andre-sponse to paclitaxel in node-positive breast cancer. N Engl JMed2007;357:1496-506.
50. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of IntergroupTrial C9741/Cancer and Leukemia Group B Trial9741.J Clin Oncol 2003;21:1431 -9.
51. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to pre- operative chemotherapy. Clin Cancer Res 2005;11: 5678-85.
52. Bonnefoi H, Potti A, Delorenzi M, etal.Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC10994/BIG 00-01 clinical trial. Lancet Oncol 2007;8:1071 -8.
53. Garber J, Richardson A, Harris L, et al. Neo- adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC). [abstract 3074] Breast Cancer ResTreat 2006;100:S149.
54. Byrski T, Gronwald J, Huzarski T, et al. Responseto neo-adjuvant chemotherapy in women with BRCA1- positive breast cancers. Breast Cancer Res Treat 2008;108:289-96.
55. Carey L, Rugo H, Marcom P, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin inmetastatic triple-negative(basal-like) breastcancer. J Clin Oncol 2008;26.
56. O'Shaughnessy J, Weckstein D, Vukelja S, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. [abstract 308]; Breast Cancer ResTreat 2007; 106(suppl1):S32.
57. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
58. Goffin JR, Straume O, Chappuis PO, et al. Glomeru- loid microvascular proliferation is associated with p53 expression, germlineBRCA1mutationsandanadverse outcome following breast cancer. Br J Cancer 2003; 89:1031 -4.
59. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine ki- nase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-6.
60. Hoadley KA, Weigman VJ, Fan C, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007;8:258.
61. Tan SH, Lee SC, Goh BC, Wong J. Pharmacogenetics in breast cancer therapy. Clin Cancer Res 2008;14:8027-42.
62. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-38.
63. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.
64. Dowsett M, DunbierAK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008;14:in press.